IL147748A0 - Use of etodolac to treat cancer - Google Patents

Use of etodolac to treat cancer

Info

Publication number
IL147748A0
IL147748A0 IL14774800A IL14774800A IL147748A0 IL 147748 A0 IL147748 A0 IL 147748A0 IL 14774800 A IL14774800 A IL 14774800A IL 14774800 A IL14774800 A IL 14774800A IL 147748 A0 IL147748 A0 IL 147748A0
Authority
IL
Israel
Prior art keywords
etodolac
treat cancer
cancer
treat
Prior art date
Application number
IL14774800A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/360,020 external-priority patent/US6545034B1/en
Application filed by Univ California filed Critical Univ California
Publication of IL147748A0 publication Critical patent/IL147748A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14774800A 1999-07-23 2000-07-13 Use of etodolac to treat cancer IL147748A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/360,020 US6545034B1 (en) 1999-07-23 1999-07-23 Use of etodolac for the treatment of chronic lymphocytic leukemia
US09/589,476 US7105560B1 (en) 1999-07-23 2000-06-07 Use of etodolac in the treatment of multiple myeloma
PCT/US2000/040370 WO2001006990A2 (en) 1999-07-23 2000-07-13 Use of etodolac to treat cancer

Publications (1)

Publication Number Publication Date
IL147748A0 true IL147748A0 (en) 2002-08-14

Family

ID=27000719

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14774800A IL147748A0 (en) 1999-07-23 2000-07-13 Use of etodolac to treat cancer

Country Status (8)

Country Link
US (1) US7105560B1 (cg-RX-API-DMAC7.html)
EP (1) EP1204412A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003529542A (cg-RX-API-DMAC7.html)
AU (1) AU785089B2 (cg-RX-API-DMAC7.html)
CA (1) CA2378371A1 (cg-RX-API-DMAC7.html)
IL (1) IL147748A0 (cg-RX-API-DMAC7.html)
NO (1) NO20020358L (cg-RX-API-DMAC7.html)
WO (1) WO2001006990A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
JP2002520282A (ja) 1998-07-09 2002-07-09 フランシス エイ. ナーデラ, 慢性リンパ性白血病の処置のための方法および組成物
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
ITMI20031471A1 (it) 2003-07-18 2005-01-19 Chemi Spa Processo per la racemizzazione dell'acido etodolico
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7321881B2 (en) * 2004-02-27 2008-01-22 Aureon Laboratories, Inc. Methods and systems for predicting occurrence of an event
TW200526668A (en) * 2003-10-02 2005-08-16 Salmedix Inc Substituted indole derivatives
WO2005050563A2 (en) 2003-11-17 2005-06-02 Aureon Biosciences Corporation Pathological tissue mapping
WO2006020627A1 (en) 2004-08-11 2006-02-23 Aureon Laboratories, Inc. Systems and methods for automated diagnosis and grading of tissue images
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
ITMI20060894A1 (it) 2006-05-05 2007-11-06 Univ Catania Ciclodestrine funzionalizzate con etodolac come agenti di rilascio sito specifico

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL107185C (cg-RX-API-DMAC7.html) 1957-12-19
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3843681A (en) * 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US4041169A (en) 1975-03-05 1977-08-09 Ayerst Mckenna And Harrison Ltd. Pharmaceutical method for using pyrano-and thiopyranoindole derivatives
US4179503A (en) 1978-05-08 1979-12-18 American Home Products Corp. 1-Hydroxyalkanamine pyrano[3,4-b]indole derivatives
US4337760A (en) 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4686213A (en) 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
CA1299577C (en) 1987-01-09 1992-04-28 John W. Gillard Tetrahydrocarbazole 1-alkanoic acids
JPS6452742A (en) 1987-04-27 1989-02-28 Syntex Pharma Int Omega-quaternary ammonium alkyl ester and thioester of acidic non-steroidal antiinflammatory
WO1993017680A1 (en) 1992-03-13 1993-09-16 Sepracor, Inc. Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
DE69527617T2 (de) 1994-04-12 2003-04-10 Arakis Ltd., Cambridge Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
AU706089B2 (en) * 1995-07-19 1999-06-10 Merck Frosst Company Method of treating colonic adenomas
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6255347B1 (en) 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IE960761A1 (en) 1996-10-31 1998-05-06 Univ Dublin City Combinations for use in increasing the potency of a¹substrate for multidrug resistance related protein
EP1920773B1 (en) * 1996-11-05 2011-01-05 The Children's Medical Center Corporation Thalidomide and dexamethasone for the treatment of tumors
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
JP2002520282A (ja) 1998-07-09 2002-07-09 フランシス エイ. ナーデラ, 慢性リンパ性白血病の処置のための方法および組成物
US7197228B1 (en) 1998-08-28 2007-03-27 Monroe David A Multifunction remote control system for audio and video recording, capture, transmission and playback of full motion and still images
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20020042375A1 (en) 2000-07-05 2002-04-11 Heimbrook David C. Method of treating cancer
EP1307459A2 (en) 2000-08-09 2003-05-07 The Regents of the University of California Indole compounds useful for the treatment of cancer
US20030004142A1 (en) 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US20030004143A1 (en) 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract

Also Published As

Publication number Publication date
US7105560B1 (en) 2006-09-12
AU7385900A (en) 2001-02-13
AU785089B2 (en) 2006-09-14
JP2003529542A (ja) 2003-10-07
NO20020358D0 (no) 2002-01-23
WO2001006990A2 (en) 2001-02-01
WO2001006990A3 (en) 2001-04-26
EP1204412A4 (en) 2004-04-21
CA2378371A1 (en) 2001-02-01
EP1204412A2 (en) 2002-05-15
NO20020358L (no) 2002-03-21

Similar Documents

Publication Publication Date Title
EG22787A (en) Treatment of coal
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
AUPQ923100A0 (en) Treatment of prostate cancer
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
AU5000001A (en) Treatment of vitiligo
HUP0200805A2 (hu) Rák javított kezelése temozolomiddal
IL130171A0 (en) Therapeutic use of melatonin
HRP20020729A2 (en) Treatment of psoriasis
GB9901838D0 (en) Slurry treatment
AU7636800A (en) Improved ricin-like toxins for treatment of cancer
AU9402401A (en) Treatment of cancers
IL149281A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
GB9819999D0 (en) Treatment of cancer
NZ514016A (en) Treatment of osteoarthritis
GB9911183D0 (en) Treatment of cancers
GB9927005D0 (en) Treatment of cancers
GB9918534D0 (en) Treatment of cancers
GB9911346D0 (en) Treatment of cancers
GB0008161D0 (en) Treatment of cancer
GB9901310D0 (en) Methods of treatment
GB9917181D0 (en) Methods of treatment
GB0025209D0 (en) Treatment of cancers
GB9908176D0 (en) Cancer treatment